BI 51013

Drug Profile

BI 51013

Alternative Names: Anti-alpha-beta-TCR monoclonal antibody BMA-031; Anti-T cell receptor alphabeta monoclonal antibody BMA031; Anti-TCR-alphabeta monoclonal antibody BMA031; Behring Monoclonal Antibody; BMA 031; Monoclonal antibody BMA031

Latest Information Update: 08 Jul 2002

Price : $50

At a glance

  • Originator Aventis Behring LLC
  • Developer Aventis Behring; Aventis Behring LLC
  • Class Monoclonal antibodies
  • Mechanism of Action T-cell receptor antigen alpha-beta antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Graft-versus-host disease; Transplant rejection
  • No development reported Renal transplant rejection

Most Recent Events

  • 24 Dec 1999 Hoechst has merged with Rhône-Poulenc to form Aventis
  • 12 Feb 1996 A preclinical study has been added to the pharmacodynamic section
  • 15 Sep 1995 A study has been added to therapeutic trials and adverse events sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top